| Literature DB >> 9674660 |
Abstract
To have the "power" of avoiding undersized clinical trials, the customary statistical strategy used in the past few decades is aimed at rejecting both a null stochastic hypothesis and a contradictory alternative hypothesis. This approach gives a trial the "power" to confirm the "insignificance" of differences much smaller than the large value of delta desired in trials done to show efficacy. In many instances, however, a prime problem is that the current "double-significance" approach produces sample sizes 2-3 times larger than needed for stochastic confirmation of large differences (> or =delta). The inflated sample sizes and consequent problems can be avoided if a realistic value for delta is chosen and maintained thereafter, and if an adequate "capacity" is calculated for "single significance."Mesh:
Year: 1998 PMID: 9674660 DOI: 10.1016/s0895-4356(98)00029-8
Source DB: PubMed Journal: J Clin Epidemiol ISSN: 0895-4356 Impact factor: 6.437